Dipharma is delighted to be featured in the 2024 edition of Global Business Reports (GBR)’s United States Life Sciences report.

In the interview, our colleagues Andrea Confetti, Exclusive Synthesis Business Unit Leader, and Roberto Fanelli, Catalogue APIs Business Unit Leader,  discuss and share their insights on Dipharma products and services.

Additionally, they explain our strategy of expanding our world-class generic API portfolio and entering new markets while continuing to strengthen our position in the CDMO space with innovative solutions. This includes leveraging and expanding our technological capabilities in both the European and US facilities.

Check out the full interview here: https://projects.gbreports.com/united-states-life-sciences-2024/dipharma-francis-interview

For more information
Paola Clerici
Communication Manager